<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-1-2-data-rasonque</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T23:05:00.000Z</news:publication_date>
      <news:title>Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CODX/co-diagnostics-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T22:00:00.000Z</news:publication_date>
      <news:title>Co-Diagnostics Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GH/guardant-reveal-ultra-launch-mrd-testing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:42:00.000Z</news:publication_date>
      <news:title>Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HYPR/hyperfine-presents-piper-sandler-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:30:00.000Z</news:publication_date>
      <news:title>Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EXOZ/exozymes-third-quarter-2026-results-business-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:25:00.000Z</news:publication_date>
      <news:title>eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLCO/bausch-lomb-phase-2-bl1332-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:15:00.000Z</news:publication_date>
      <news:title>Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-corporate-update-call-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:15:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MEDS/datameds-ai-acquires-tbia-cancer-ai-platform</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:11:00.000Z</news:publication_date>
      <news:title>DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZR/azora-therapeutics-inducement-grant-nasdaq-rule-5635</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:10:00.000Z</news:publication_date>
      <news:title>Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SIBN/si-bone-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:09:00.000Z</news:publication_date>
      <news:title>SI-BONE To Present at Piper Sandler 38th Annual Healthcare Conference on December 1, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-piper-sandler-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Pulse Biosciences to Present at Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LAB/standard-biotech-merger-treeline-biosciences-approval</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RXST/rxsight-presents-piper-sandler-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>RxSight, Inc. to Present at the Piper Sandler Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CLDX/celldex-phase-2-barzolvolimab-atopic-dermatitis-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:01:00.000Z</news:publication_date>
      <news:title>Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KMDA/kamada-tax-ruling-dividend-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:01:00.000Z</news:publication_date>
      <news:title>Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NTHI/neonc-fda-rescheduled-neo212-meeting-november-23</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:38:13.000Z</news:publication_date>
      <news:title>NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BIIB/lecanemab-clarity-ad-csf-substudy-findings-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:35:27.000Z</news:publication_date>
      <news:title>Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HLF/herbalife-launches-fuel-her-power-nutrition-guide</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:31:00.000Z</news:publication_date>
      <news:title>Herbalife Launches Fuel Her Power, a Nutrition Guide for Active Women</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COSM/cosmos-health-resume-share-repurchases-lock-up</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T15:30:00.000Z</news:publication_date>
      <news:title>Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BDX/bd-85-years-medical-device-manufacturing-glens-falls</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:30:00.000Z</news:publication_date>
      <news:title>BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CING/cingulate-ct-2103-patent-issuance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:29:00.000Z</news:publication_date>
      <news:title>Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NXGL/nexgel-postpones-q3-2026-conference-call</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:25:00.000Z</news:publication_date>
      <news:title>NEXGEL Postpones Third Quarter 2026 Financial Results and Corporate Update Conference Call to November 24th</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HALO/halozyme-update-german-injunction-hearing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:20:00.000Z</news:publication_date>
      <news:title>Halozyme Provides Update on German Preliminary Injunction Hearing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:09:00.000Z</news:publication_date>
      <news:title>Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LEXX/lexaria-human-study-glp-1-h26-7-completes-dosing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:05:33.000Z</news:publication_date>
      <news:title>Lexaria’s Human Study GLP-1-H26-7 Completes Dosing as Scheduled</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHG/philips-advanced-image-insights-ai-orchestration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Philips introduces Advanced Image Insights for advanced visualization and AI orchestration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABT/abbott-voyager-trial-encantor-tavi-system</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MODD/modular-medical-secures-pbm-coverage-agreements</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Modular Medical Secures Coverage Agreements with All Three of the Nation&apos;s Largest PBMs for Pivot Insulin Delivery System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ottava-robotic-surgical-system-installation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:51:00.000Z</news:publication_date>
      <news:title>Johnson &amp; Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-canadian-patent-ovarian-cancer-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:45:00.000Z</news:publication_date>
      <news:title>Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SSII/ss-innovations-dual-console-beating-heart-tecab-surgery</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>SS Innovations Announces World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra Surgical Robotic System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MSA/msa-safety-welcomes-stanley-elliott-vp-investor-relations</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>MSA Safety Welcomes Stanley Elliott as Vice President, Investor Relations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VOGX/vogenx-joins-russell-indexes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCA/hca-healthcare-crush-the-crisis-2023</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>HCA Healthcare Collects Record-Breaking 21,857 Pounds of Medication During Eighth Annual “Crush the Crisis”</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IBRX/immunitybio-fastest-growing-technology-company</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-appoints-daniel-bradbury-chairman</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ICUI/icu-medical-piper-sandler-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-richard-stark-board-directors</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-10-million-treatments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:09:07.466Z</news:publication_date>
      <news:title>Bausch Health&apos;s Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-participate-upcoming-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:05:00.000Z</news:publication_date>
      <news:title>Harmony Biosciences to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VIVS/vivosim-labs-seven-figure-agreement-pharma-company</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:05:00.000Z</news:publication_date>
      <news:title>VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/jnj-caplyta-fda-approval-bipolar-mania</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:01:00.000Z</news:publication_date>
      <news:title>Johnson &amp; Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APMD/national-survey-people-sleep-apnea-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:38.000Z</news:publication_date>
      <news:title>New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-mangaciclanol-phase-3-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HUMA/humacyte-sbla-hemodialysis-access-atev</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-gerd-awareness-week-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IRLA/irulya-therapeutics-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>IRulya Therapeutics to Participate in the 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALT/altimmune-participate-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Altimmune to Participate in the 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TVRD/tvardi-advances-tti-109-ind-in-ibd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-third-quarter-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VBIO/valion-bio-dr-armand-balboni-advisor-entolimod-data-readout</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:45:00.000Z</news:publication_date>
      <news:title>Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1530-clinical-activity-ena-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:39:12.664Z</news:publication_date>
      <news:title>Biohaven&apos;s Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMND/clearmind-medicine-ptsd-patent-hong-kong</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:32:00.000Z</news:publication_date>
      <news:title>Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STEX/streamex-monetary-metals-gold-yield-iras</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:27.000Z</news:publication_date>
      <news:title>Streamex Corp. and Monetary Metals &amp; Co. Expand Partnership to Unlock Gold Yield in IRAs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorin-docetaxel-empd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:13.000Z</news:publication_date>
      <news:title>Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZTS/zoetis-usda-license-poulvac-procerta-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/USPH/us-physical-therapy-southwest-ideas-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>U.S. Physical Therapy Presented at the 18th Annual Southwest IDEAS Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDCX/medicus-pharma-regains-compliance-nasdaq-minimum-equity-requirement-continued-listing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GSK/velzatinib-odd-japan-gist</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:25:35.000Z</news:publication_date>
      <news:title>Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PASG/remix-therapeutics-rem-422-phase-1-data-eortc-nci-aacr</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:15:58.000Z</news:publication_date>
      <news:title>Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GNPX/genprex-trop2-predictive-biomarker-reqorsa-lung-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:12:19.262Z</news:publication_date>
      <news:title>Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/aetna-for-you-baby-initiative-2032</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Aetna Commits to Connecting 90% of Members to Essential, End-to-End Maternal and Infant Care by 2032 with Launch of the Aetna For You &amp; Baby Initiative</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SER/enable-injections-arespo-partnership-aatd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Enable Injections and ARespo Biopharma Announce Strategic Partnership</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KPRX/kiora-kio-401-late-stage-therapeutics</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVCR/novocure-announces-upcoming-investor-events</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Novocure Announces Upcoming Investor Events</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALNY/alnylam-regeneron-fda-approval-livsayis-cemdisiran</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam&apos;s RNAi Platform in Less Than Nine Years</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/REGN/regeneron-new-data-ash-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ATYR/atyr2810-preclinical-data-ctos-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KRRO/korro-participate-upcoming-investor-conferences-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Korro to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADAG/adagene-phase-1-study-adg138-dosing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVAX/evaxion-strategy-update-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Evaxion announces strategy and business update and third quarter 2026 financial results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-cprit-grant-mt-601-phase-2</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Axsome Therapeutics to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-annual-report-filing-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-rdh12</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-ash-2026-blood-cancers</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:59:00.000Z</news:publication_date>
      <news:title>Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conference-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:55:00.000Z</news:publication_date>
      <news:title>ANI Pharmaceuticals to Present at Upcoming December Investor Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CDT/cdt-sarborg-sale-cryptocurrency-agent</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:45:00.000Z</news:publication_date>
      <news:title>CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRK/merck-isomorphic-labs-research-collaboration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:45:00.000Z</news:publication_date>
      <news:title>Merck and Isomorphic Labs Enter Strategic Research Collaboration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMPS/compass-pathways-evercore-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:30:00.000Z</news:publication_date>
      <news:title>Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HIT/health-in-tech-expands-distribution-tpa-100k-employees</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:30:00.000Z</news:publication_date>
      <news:title>Health In Tech Expands National Distribution Through TPA Serving More Than 100,000 Employees</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BDX/bd-time-2027-top-manufacturers</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:00:00.000Z</news:publication_date>
      <news:title>BD Named to TIME&apos;s 2027 List of America&apos;s Top Manufacturers</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-upcoming-investor-conferences-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:00:00.000Z</news:publication_date>
      <news:title>Zymeworks Announces Participation in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-nmpa-approval-sovleplenib-itp-waiha</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T10:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/jacobs-sanofi-insulin-manufacturing-germany</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T08:30:00.000Z</news:publication_date>
      <news:title>Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DXCM/dexcom-athenry-opening-commercial-production-milestone</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:30:00.000Z</news:publication_date>
      <news:title>Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVO/evotec-bristol-myers-squibb-second-ind-acceptance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:06:00.000Z</news:publication_date>
      <news:title>Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABBV/disco-abbvie-collaboration-bispecific-therapeutics</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:00:00.000Z</news:publication_date>
      <news:title>DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVS/novartis-sales-cagr-growth-2031</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:00:00.000Z</news:publication_date>
      <news:title>Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/sanofi-vaxrabeo-eu-approval-rabies-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:00:00.000Z</news:publication_date>
      <news:title>Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SBC/sbc-medical-group-cybersecurity-incidents-japan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:39:00.000Z</news:publication_date>
      <news:title>SBC Medical Group Reports Cybersecurity Incidents in Japan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-150-0-million-underwritten-public</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T02:59:00.000Z</news:publication_date>
      <news:title>SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EMMA/emmaus-life-sciences-quarterly-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T01:05:00.000Z</news:publication_date>
      <news:title>Emmaus Life Sciences Reports Quarterly Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMMP/immutep-eftisarc-neo-phase-ii-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:12:00.000Z</news:publication_date>
      <news:title>Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-hmpl-a830-preclinical-data-eortc-nci-aacr</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/REGN/livsayis-fda-approval-gmg-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:03:00.000Z</news:publication_date>
      <news:title>Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OSCR/hy-vee-health-oscar-expansion-iowa-kansas-city-omaha</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:03:00.000Z</news:publication_date>
      <news:title>Hy-Vee Health with Oscar Expands Across Iowa, Into Kansas City and Omaha for 2027 Open Enrollment</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-phase-1-data-webcast</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:01:00.000Z</news:publication_date>
      <news:title>Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-nasdaq-listing-rule-5635-c-4-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:41:00.000Z</news:publication_date>
      <news:title>Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/infilbray-approved-first-treatment-type-3-gaucher-disease</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:19:00.000Z</news:publication_date>
      <news:title>Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HYFT/mindwalk-2026-agm-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:01:00.000Z</news:publication_date>
      <news:title>MindWalk Announces Results of 2026 Annual General Meeting of Shareholders</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TEVA/teva-rd-leadership-transition-eric-hughes-departure</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:00:00.000Z</news:publication_date>
      <news:title>Teva Announces R&amp;D Leadership Transition; Eric Hughes to Depart the Company</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-webcast-qtorin-program</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:00:00.000Z</news:publication_date>
      <news:title>Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRM/medirom-nasdaq-delisting-notice-annual-report-filing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:45:00.000Z</news:publication_date>
      <news:title>MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSPR/inspiremd-first-us-commercial-tcar-procedures</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:30:00.000Z</news:publication_date>
      <news:title>InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-participate-upcoming-investor-conferences-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:30:00.000Z</news:publication_date>
      <news:title>Cytek Biosciences to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UHS/universal-health-services-dividend-announcement</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:20:29.000Z</news:publication_date>
      <news:title>Universal Health Services, Inc. Announces Dividend</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/A/agilent-announces-cash-dividend-26-25-cents-per-share</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Agilent Announces Cash Dividend of 26.25 Cents per Share</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARDT/ardent-health-eight-facilities-a-hospital-safety-grade</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Eight Ardent Health Facilities Earn ‘A’ Hospital Safety Grades from The Leapfrog Group for Fall 2026 Grading Period</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grants-nasdaq-5635c4</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PROK/prokidney-names-farah-ali-cmo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LUNG/pulmonx-piper-sandler-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:31.000Z</news:publication_date>
      <news:title>Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TCMD/tactile-medical-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Tactile Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELOX/elox-phase-2a-exaluren-data-alport-syndrome</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-conferences-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Arcus Biosciences to Participate in Two Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLLN/billiontoone-responds-short-seller-report</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>BillionToOne Responds to Inaccurate and Misleading Short Seller Report</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/INNV/innovage-holding-corp-settlement-doj</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>InnovAge Holding Corp. Resolves Civil Matter with U.S. Department of Justice &amp; Participating States</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-awards-nasdaq-mdgl</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:04:00.000Z</news:publication_date>
      <news:title>Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMCC/im-cannabis-share-consolidation-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>IM Cannabis Announces Intention to Complete 3:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALGN/align-technology-board-appointments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LKFT/lakefront-new-subscription-right-plan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>Lakefront Creates New Subscription Right Plan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GMAB/genmab-restricted-stock-units-warrants-employees</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T19:40:00.000Z</news:publication_date>
      <news:title>Grant of Restricted Stock Units and Warrants to Employees in Genmab</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TVGN/tevogen-significant-liability-reduction-insider-control</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T19:30:00.000Z</news:publication_date>
      <news:title>Tevogen Highlights Significant Liability Reduction and Continued Insider Control</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MOH/molina-healthcare-illinois-commitment-expansion-access-care</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T17:45:00.000Z</news:publication_date>
      <news:title>Molina Healthcare of Illinois Commits $2.4 Million to Expand Access to Care Across the State</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDLN/medline-launches-ranpak-packaging-solutions</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T17:26:00.000Z</news:publication_date>
      <news:title>Medline launches right-sized Ranpak packaging solutions in two key distribution centers</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BIIB/new-three-year-leqembi-data-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T16:00:51.000Z</news:publication_date>
      <news:title>New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COSM/cosmos-health-reports-record-revenue-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:25:00.000Z</news:publication_date>
      <news:title>Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders&apos; Equity Up 21% Since Year-End</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-karxt-alzheimers-psychosis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:10:00.000Z</news:publication_date>
      <news:title>Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHG/philips-skylight-device-manager-ultrasound-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:00:00.000Z</news:publication_date>
      <news:title>Philips introduces Skylight Device Manager to turn ultrasound data into operational intelligence</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLRX/biolinerx-q3-2026-results-conference-call</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:00:00.000Z</news:publication_date>
      <news:title>BioLineRx to Report Third Quarter 2026 Results on November 23, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-advanced-visualization-inteleviewer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare brings advanced visualization into InteleViewer to support radiology workflows</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VSTM/verastem-oral-presentation-vs-7375-lung-cancer-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:00:00.000Z</news:publication_date>
      <news:title>Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HIMS/hims-launches-peptides-personalized-health</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T14:00:00.000Z</news:publication_date>
      <news:title>Hims &amp; Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APUS/apimeds-pharmaceuticals-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:44:00.000Z</news:publication_date>
      <news:title>Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MBRX/moleculin-global-ip-portfolio-annamycin-patent-korea</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:35:15.000Z</news:publication_date>
      <news:title>Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRMA/dermata-trademark-registration-tome</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:35:00.000Z</news:publication_date>
      <news:title>Dermata Announces U.S. Trademark Registration for TOME(R)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANIX/anixa-curia-breast-cancer-vaccine-phase-2</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:33:52.022Z</news:publication_date>
      <news:title>Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MSA/msa-safety-awarded-scba-contract-montreal-fire-departments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:30:00.000Z</news:publication_date>
      <news:title>MSA Safety Awarded SCBA Contract By Greater Montreal Fire Departments</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TMO/thermo-fisher-gibco-vaxevo-cd-293-medium-launch</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:30:00.000Z</news:publication_date>
      <news:title>Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRVA/privia-health-2025-medicare-savings-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:30:00.000Z</news:publication_date>
      <news:title>Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AIM/aim-immunotech-adjourns-2026-annual-meeting</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:30:00.000Z</news:publication_date>
      <news:title>AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVAX/evaxion-strategy-business-update-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:30:00.000Z</news:publication_date>
      <news:title>Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ICCM/icecure-reports-financial-results-september-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:25:00.000Z</news:publication_date>
      <news:title>IceCure Reports Financial &amp; Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELAN/elanco-participate-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:22:00.000Z</news:publication_date>
      <news:title>Elanco to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNN/smith-nephew-jami-bliss-ism-board</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:18:17.062Z</news:publication_date>
      <news:title>ISM Names Smith+Nephew Global Head of Procurement Jami Bliss to Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/YCBD/cbdmd-hemp-guardrails-act-support</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:10:00.000Z</news:publication_date>
      <news:title>cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NNOX/nanox-showcase-innovative-technology-rsna-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:10:00.000Z</news:publication_date>
      <news:title>Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLLN/billiontoone-piper-sandler-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:05:00.000Z</news:publication_date>
      <news:title>BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/INO/inovio-submits-cma-application-voceryq-rrp</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:05:00.000Z</news:publication_date>
      <news:title>INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/QTRX/quanterix-leadership-transition-plan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:03:00.000Z</news:publication_date>
      <news:title>Quanterix Announces Leadership Transition Plan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRE/prenetics-q3-2026-revenue-growth</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:02:43.000Z</news:publication_date>
      <news:title>Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SPAI/safe-pro-wins-mine-action-innovation-award</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:02:26.000Z</news:publication_date>
      <news:title>Safe Pro Wins Mine Action Innovation Award Sponsored by the European Union at the 2026 Ukraine Mine Action Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RTSN/retension-pharmaceuticals-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:22.000Z</news:publication_date>
      <news:title>Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-aha-2026-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:19.000Z</news:publication_date>
      <news:title>Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DXR/daxor-expands-bva-adoption-memphis-hospital</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Major Memphis Health System Expands BVA® Adoption to New Hospital Outpatient Site</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IGC/igc-pharma-phase-2-calma-trial-completion</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer&apos;s Dementia</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LTRN/lantern-pharma-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WGS/genedx-announces-leadership-transition</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>GeneDx Announces Leadership Transition</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ENLV/enlivex-positive-dsmb-review-phase-iib-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-melanoma-data-ena-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-linical-fda-phase-1-2-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IAM/iambic-preclinical-data-cdk2-4-inhibitor-iam-c1</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T13:00:00.000Z</news:publication_date>
      <news:title>Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-us-patent-stenoparib</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:50:00.000Z</news:publication_date>
      <news:title>Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STEX/streamex-glody-live-equity-trust-ira</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:49.000Z</news:publication_date>
      <news:title>Streamex Corp. Announces GLDY Is Now Live at Equity Trust Company, Its First Tokenized Asset for Self-Directed IRAs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMNM/immunome-present-upcoming-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Immunome to Present at Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-fastest-growing-company-deloitte-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OPTH/optimi-health-2027-plans-opti-101-opti-201</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMRX/immuneering-expands-clinical-evaluation-atebimetinib-atc</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMRX/immuneering-atebimetinib-pancreatic-cancer-combination-therapy</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SGRY/surgery-partners-increases-consent-fee-solicitation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:30:00.000Z</news:publication_date>
      <news:title>Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NGEN/nervgen-appoints-sam-jackson-cmo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:15:00.000Z</news:publication_date>
      <news:title>NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GSK/nelkarmi-approval-advanced-alk-positive-lung-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:06:13.000Z</news:publication_date>
      <news:title>Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NBP/visara-first-patient-ascend-phase-2b-trial-vis-101</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:00:00.000Z</news:publication_date>
      <news:title>Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UNH/unitedhealthcare-cpesn-new-care-delivery-model</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:00:00.000Z</news:publication_date>
      <news:title>UnitedHealthcare and CPESN Announce New Care Delivery Model Expanding Access to Care in Rural and Underserved Communities Through Independent Pharmacies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLRX/biolinerx-royalty-monetization-transaction</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:00:00.000Z</news:publication_date>
      <news:title>BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:00:00.000Z</news:publication_date>
      <news:title>Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CANF/can-fite-phase-iii-psoriasis-study-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T12:00:00.000Z</news:publication_date>
      <news:title>Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PFE/pfizer-exclusive-licensing-agreement-starna-therapeutics</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:45:00.000Z</news:publication_date>
      <news:title>Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRK/thomas-glocer-retire-merck-board-2027</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:45:00.000Z</news:publication_date>
      <news:title>Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HIT/health-in-tech-appoints-tim-cortes-independent-director</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:30:00.000Z</news:publication_date>
      <news:title>Health In Tech Appoints Tim Cortes as Independent Director, Chair of the Compensation Committee</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HAE/haemonetics-vascade-mvp-xl-ce-mark-certification</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:15:00.000Z</news:publication_date>
      <news:title>Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MEDS/datameds-ai-helomics-dia-gen-partnership-cancer-drug-development</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:00:00.000Z</news:publication_date>
      <news:title>DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-phase-iii-harmoni-10-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T11:00:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-11-16</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T10:45:37.901Z</news:publication_date>
      <news:title>PepGen&apos;s PGN-EDODM1 Phase 2 Data Readout: Phase 2 and 3 Readouts Nov 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MMM/3m-cooling-film-transportation-efficiency</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T10:13:00.000Z</news:publication_date>
      <news:title>New 3M™ Cooling Film helps fleet and rail operators keep cabin interiors cooler and improve efficiency</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RXRX/recursion-fda-alignment-phase-3-trial-rec-4881-fap</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T09:59:00.000Z</news:publication_date>
      <news:title>Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-clonoseq-ash-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T08:00:00.000Z</news:publication_date>
      <news:title>Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TRDA/entrada-elevate-45-201-cohort-3-15mgkg</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T08:00:00.000Z</news:publication_date>
      <news:title>Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IPHA/innate-pharma-ip4502-phase-1-data-ena-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T07:30:00.000Z</news:publication_date>
      <news:title>Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OLMA/olema-oncology-kat6a-degraders-eortc-nci-aacr</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T07:30:00.000Z</news:publication_date>
      <news:title>Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/INSP/nyxoah-default-decision-inspire-patent-case</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T07:00:00.000Z</news:publication_date>
      <news:title>Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVS/novartis-hematology-breast-cancer-ash-sabcs-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T06:00:00.000Z</news:publication_date>
      <news:title>Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVO/novo-nordisk-foundation-carb-x-antimicrobial-resistance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T06:00:00.000Z</news:publication_date>
      <news:title>Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDLN/medline-secondary-offering-class-a-stock</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T03:23:00.000Z</news:publication_date>
      <news:title>Medline Inc. announces pricing of secondary offering of Class A common stock</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARDT/ardent-health-secondary-offering-pricing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T01:53:00.000Z</news:publication_date>
      <news:title>Ardent Health Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRIO/dario-secures-second-womens-health-contract</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00.000Z</news:publication_date>
      <news:title>Dario Secures Second Women&apos;s Health Contract in Just Weeks with The Minnesota Star Tribune</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ERAS/erasca-clinical-collaboration-bms-navlimetostat</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T23:40:00.000Z</news:publication_date>
      <news:title>Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat</news:title>
    </news:news>
  </url>
</urlset>